Jim Simons Corvus Pharmaceuticals, Inc. Call Options Transaction History
Renaissance Technologies LLC
- $63.6 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRVS
# of Institutions
51Shares Held
18.3MCall Options Held
29.9KPut Options Held
30.2K-
Orbimed Advisors LLC San Diego, CA6.94MShares$12.6 Million0.28% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$5.96 Million2.56% of portfolio
-
Samlyn Capital, LLC New York, NY2.35MShares$4.27 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.49MShares$2.72 Million0.0% of portfolio
-
Black Rock Inc. New York, NY523KShares$951,8190.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $84.7M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...